Skip to main content

O'Melveny & Myers, Tian Yuan Law Firm and William Ji & Co. have represented China’s Simcere Pharmaceutical Group on its HK$3.57 billion ($460.6 million) Hong Kong IPO, with Herbert Smith Freehills and Jingtian & Gongcheng advising the joint sponsors.

The listing is the latest by a Chinese biopharmaceutical company in Hong Kong, which is on track to have its second-busiest year for equity capital markets ever in 2020. Recent such issuers include JHBP (CY) Holdings and Everest Medicines.

Simcere Pharmaceutical supplies branded generic pharmaceuticals to the Chinese market. It has increased investment in R&D in recent years, and has three R&D centres in Nanjing, Shanghai and Boston.

Partners Matt Emsley, Siddhartha Sivaramakrishnan and Stanley Xie led the Herbert Smith Freehills team.

 

To contact the editorial team, please email ALBEditor@thomsonreuters.com. 

Related Articles

Deals

Khaitan, JSA, Hogan Lovells guide $515 mln Waaree IPO

by Nimitt Dixit |

Khaitan & Co has advised Waaree Energies, India's largest manufacturer and exporter of solar modules, on its $515 million initial public offering, with JSA Advocates & Solicitors and Hogan Lovells guiding the bookrunning lead managers.

Deals

CAM, Khaitan guide Adani-backed Renew Exim’s $380 mln ITD acquisition

by Nimitt Dixit |

Cyril Amarchand Mangaldas has advised Adani Group's Dubai-based firm Renew Exim DMCC on its acquisition of a 46.64 percent stake in ITD Cementation India for around $380 million from Italian-Thai Development Public Company, who was represented by Khaitan & Co.

Deals

CAM, AZB, SAM, Latham advise on landmark $1.3 bln Swiggy IPO

by Nimitt Dixit |

Cyril Amarchand Mangaldas is advising SoftBank-backed Indian food and grocery delivery giant Swiggy on its much-anticipated initial public offering worth $1.3 billion, with AZB & Partners and Latham & Watkins advising the bookrunning lead managers.